·s«¬SGLT2§í¨î¾¯¡@ºC©ÊµÇŦ¯e¯f²Ä¤T´ÁÁ{§É¸ÕÅç¹F¼Ð
·s«¬SGLT2§í¨î¾¯¦b¬ü°ê¤wÀò±o§åã¥Î©óµL½×¦³µL¿}§¿¯fªº§C¦¬ÁY¤À²v¤ßŦ°IºÜ±wªÌ¡A´î¤Ö¤ß¦]©Ê¦º¤`©M¤ßŦ°IºÜ¦í°|·ÀI¡C¼Ú¬wÃĪ«ºÞ²z§½¥H¤Î¨ä¥L¦a°Ï¤]¥¿¦b¼f¬d¨äªvÀø¤ßŦ°IºÜªº¥Ó½Ð¡C
¿}§¿¯f·sÃÄ¡A¦³§U´î½wºC©ÊµÇŦ¯f¶iµ{¡I°ê»Ú¤jÃļtªü´µ¯S±¶§Q±d¡]AstraZeneca¡^¤é«e¿}§¿¯f·sÃÄSGLT2§í¨î¾¯ªº²Ä¤T´ÁÁ{§É¸ÕÅçDAPA-CKD¡A¦]®ÄªGÅãµÛ´£¦µ²§ô¸ÕÅç¡Aªñ´Á¤½¥¬¸ÕÅç²×ÂI¼Æ¾ÚÅã¥Ü¡AµL½×¦³µL²Ä¤G«¬¿}§¿¯f¡A¸ÓÃĪ«°§C¤FºC©ÊµÇŦ¯e¯f±wªÌªºµÇ¥\¯à´c¤Æ©Î¦º¤`·ÀI¡C
·s«¬SGLT2§í¨î¾¯¡@ºC©ÊµÇŦ¯e¯f¸ÕÅçµ²ªG¨}¦n
®Ú¾Ú¡m¸ô³zªÀ¡n³ø¾É¡A¿}§¿¯f®e©ö³y¦¨¤ßŦ¡BµÇŦ¡B²´·úµ¥¾¹©x¨Öµo¯g¡A¦]¦¹³\¦h¿}§¿¯f·sÃĸչϰ§C³oÃþ¾¹©xªº¶Ë®`¡C
¨ä¤¤¡A·s«¬SGLT2§í¨î¾¯¬O¤@ºØ¶u-¸²µå¿}¦@Âà¹B³J¥Õ2§í¨î¾¯¡]Sodium glucose cotransporter 2 inhibitors, SGLT2 inhibitors¡^¡Aì¥Î©óªvÀø¦¨¤H²Ä2«¬¿}§¿¯f±±¨î¤£¨Î¡A§@¬°³æ¤@Àøªk¡A¤]¥i¬°¦X¨ÖªvÀøªº¤@³¡¤À¡A»²§U¶¼¹©M¹B°Ê¥H§ïµ½¦å¿}±±¨î¡A¨Ã¦³§U´î¤ÖÅé«©M°§C¦åÀ£µ¥ÃB¥~¯q³B¡C
²Ä¤T´ÁÁ{§É¸ÕÅçDAPA-CKD¡A¬°µû¦ôSGLT2§í¨î¾¯»P¦w¼¢¾¯¬Û¤ñ¡A¥Î©ó²Ä2-4´ÁºC©ÊµÇŦ¯f¦X¨Ö³J¥Õ§¿¡B¦³©ÎµL²Ä2«¬¿}§¿¯f¯f±wªºÀø®Ä¡C
²Ä¤T´ÁÁ{§É¸ÕÅçDAPA-CKD µ²ªGÅã¥Ü¡A·s«¬SGLT2§í¨î¾¯¹F¨ì¥Dn¸ÕÅç²×ÂI¡A²Îp¾Ç¤WÅãµÛ¥B¨ãÁ{§É·N¸qªº´î¤ÖºC©ÊµÇŦ¯f¡]Chronic Kidney Disease, CKD¡^±wªÌªºµÇ¥\¯à´c¤Æ©Î¦º¤`·ÀI¡]©w¸q¡G«ùÄò¤j©ó50%ªºµÇ¥\¯à¤U°¡B·sµo¥Í¥½´ÁµÇŦ¯f¡B¤ß¦]©Ê©ÎµÇ¦]©Ê¦º¤`¡^¡C¹ï©óµL½×¦³©ÎµL¿}§¿¯fªºCKD¯f±w¡A¸Ó¸ÕÅçÁÙ¹F¨ì©Ò¦³¦¸n¸ÕÅç²×ÂI¡A¨Ï·s«¬SGLT2§í¨î¾¯¦¨¬°²Ä¤@Ó¯àÅãµÛ´î¤Ö¦¹±Ú¸s¯f±w¥þ¦º¦]¦º¤`·ÀIªºÃĪ«¡C
ºC©ÊµÇŦ¯f¬O¤@ºØÄY«¥B«ùÄò´c¤Æªº¯e¯f¡A¨ä¯S¼x¬OµÇ¥\¯à¤U°¡A¼vÅT¥þ²yªñ7»õ¤H¡A¨ä¤¤³\¦h¤H©|¥¼½T¶E¡C¥Ø«e³o¨Ç±wªÌªºªvÀø¿ï¾Ü¦³¡CºC©ÊµÇŦ¯f»P¤ß¦åºÞ¨Æ¥ó·ÀI¼W¥[¦³Ãö¡A¦p¤ßŦ°IºÜ©M¹L¦¦º¤`¡C
¦³§U°§C¦º¤`·ÀI¡@ºC©ÊµÇŦ¯f±wºÖµ
¸ÕÅç°õ¦æ©eû·|ªºÁp¦X¥D®u¡AÛ´°¤j¾Ç¾Ç°|ªºDavid Wheeler±Ð±Â¡A©M®æù¹ç®Ú¤j¾ÇÂå¾Ç¤¤¤ßªºHiddo L. Heerspink±Ð±Â»¡¡G¡u DAPA-CKD¸ÕÅçÅã¥Ü·s«¬SGLT2§í¨î¾¯ªº¼ç¤O¡A§@¬°§Ú̵¥«Ý¤w¤[ªººC©ÊµÇŦ¯f±wªº·sªvÀø¿ï¾Ü¡A³o¨Ç¼Æ¾Ú±N¹ï±wªÌ¨ã«¤j·N¸qªº§ïÅÜ¡C¡v
ªü´µ§Q±¶§Q±d¥Íª«»sÃĬãµo³¡°õ¦æ°ÆÁ`µôMene Pangalosªí¥Ü¡G¡u DAPA-CKD¬O²Ä¤@Ó¦bCKD±wªÌ¤¤ÃÒ©úÀ£Ë©Êµ²ªGªº¸ÕÅç¡A¥]¬A´£°ª¦s¬¡²v¡AµL½×¬O§_¦X¨Ö¦³²Ä¤G«¬¿}§¿¯f¡C§ÚÌ´Á«ÝµÛ»P¥@¬É¦U¦aªº¬ì¾Ç¬É©M½Ã¥Í¥DºÞ³æ¦ì¤À¨É³o¨Ç¥O¤H¿³¾Äªº¦¨ªG¡C¡v
¾Ú±x¡A¦b2020¦~3¤ë¡Aªü´µ¯S±¶§Q±d¤½¥q¤w«Å¥¬DAPA-CKD¸ÕÅç±N´£«e²×¤î¡A°ò©ó¿W¥ß¼Æ¾ÚºÊ´ú©eû·|®Ú¾Ú©Ò½T©wªºÀ£Ë©ÊÀø®Ä´£¥Xªº«Øij¡C
¦¹¥~¡A¦b2020¦~5¤ë¡A·s«¬SGLT2§í¨î¾¯¦b¬ü°ê¤wÀò±o§åã¥Î©óµL½×¦³µL¿}§¿¯fªº§C¦¬ÁY¤À²v¤ßŦ°IºÜ±wªÌ¡A´î¤Ö¤ß¦]©Ê¦º¤`©M¤ßŦ°IºÜ¦í°|·ÀI¡C¼Ú¬wÃĪ«ºÞ²z§½¥H¤Î¨ä¥L¦a°Ï¤]¥¿¦b¼f¬d¨äªvÀø¤ßŦ°IºÜªº¥Ó½Ð¡C